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Dr Richard G. Ohye (Ann Arbor, Mich). Congratulations, Dr
Caputo and colleagues, for completing this trial.
I have 2 questions. As background, I think, the majority of us
either do use or would feel very comfortable using normothermia
in these straightforward operations with short or limited bypass
times. What is the applicability to other cases that are more com-
plex or that have longer bypass times? How may your data be ap-
plicable to neonates and more complex operations?
What was the reason for excluding neonates? Do you think that
there is anything unique in their anatomy or physiology that may
make these data applicable or not applicable?
Similarly, for more complex operations with longer bypass
times, did you look at interactions between with bypass time and1120 The Journal of Thoracic and Cardiovascular Suryour outcomes that may show a greater or lesser effect at longer
bypass times? It is those more complex operations in which these
data may be more applicable.
My second question relates to your graphs, which consistently
show a suggestion of a benefit for normothermia, although not sta-
tistically significant. Are you willing to speculate that normother-
mia might not only be worse, but might be beneficial compared
with moderate hypothermia?
Dr Caputo. The reason we excluded neonates to start with was
that, as in many other units, we were using hypothermia routinely,
and to start the trial, we decided that for neonates wewere not com-
fortable using normothermia.
The trial actually is still ongoing, because the second part of this
trial will look at clinical outcomes, and the sample size for that is
around 300 patients. For that we are excluding only patients who
require hypothermic circulatory arrest. For example, we are now
doing switches with normothermia for sure.
In terms of the effect of CPB time on these markers, we did not
look specifically at the relationship and it is probably worthwhile
doing that.
Dr Ohye. Are you willing to commit that normothermia may
actually be beneficial compared with hypothermia?
Dr Caputo. Personally, I feel much more comfortable with nor-
mothermia, because I really believe that cooling and rewarming
are actually detrimental for several organs, and I think the kidney
is one of them.
Dr Constantine Mavroudis (Cleveland, Ohio). I wonder
about the rate of myocardial rewarming during cardioplegic ar-
rest during normothermic CPB caused by collateral flow or organ
proximity to the heart. Do you plan to use myocardial tempera-
ture measurements in the future? In addition, in retrospect, did
you notice with your normothermic group that the cardioplegia
administration did not last as long as determined by immergence
of electrical activity? Was there evidence of myocardial dysfunc-
tion after the operation? I think most people would use hypother-
mia not only for flow reasons but also to protect against
myocardial rewarming. What are your thoughts about these
issues?
Dr Caputo. Yes, we did look at the heart, and this was actually
published a couple years ago.When we looked at markers of ische-
mia–reperfusion injury and reoxygenation injury in these 2 groups,
we noticed that the normothermic group had less, for example, tro-
ponin I or 8–isoprostane release. Again, we do not believe that
there are detrimental effects on the heart. On the contrary, in terms
of reoxygenation injury, we might believe that normothermic CPB
was beneficial.
In the same study we did evaluate the inflammatory response
of the 2 techniques, and there was no difference. I am pretty con-
fident that normothermia is safe for the heart. In fact, there is
now evidence from groups in Paris using warm plegia, even
though these are retrospective analyses, but they achieve quite
good outcomes.
Dr Tara Karamlou (Seattle, Wash). I have 2 quick questions:
First, can you briefly talk about your protocol regarding ultrafiltra-
tion? Did you use modified ultrafiltration in both groups equally? I
wonder whether some of the markers that you are measuring could
be affected by the use of modified ultrafiltration, especially in the
short term.gery c November 2011
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DSecond, was this study adequately powered and are we sure this
is not just a statistical type II error, since you found no difference in
many of your outcome measures?
Dr Caputo.We did not use modified ultrafiltration in these pa-
tients because they were not neonates. Normally we tend to use
modified ultrafiltration in patients weighing below 5 kg, so they
did not receive ultrafiltration. Also, we measured the hematocrit
of all these patients.
Dr Karamlou. Thus even if you were not using modified ultra-
filtration, what was the perfusion strategy in terms of using filtra-
tion during the bypass times?
DrCaputo.These patients specifically were not subjected to fil-
tration during bypass, and the hematocrit was the same at all the
time points for the 2 groups. We did measure the hematocrit levels.
Also, the renal function was actually in the urine, so the main
markers are expression of the glomerular damage and tubular dam-
age in the urine according to the glomerular filtration rate. That is
the reason we looked at the ratio between the markers and the cre-
atinine in the urine.
Please remind me of the second question.
Dr Karamlou. The second question was about power.
Dr Caputo. Yes, the power for these markers was based on our
previous experience, and the sample size calculation was done on
the area under the curve of these markers previously measured inThe Journal of Thoracic and Carsimilar studies. Thirty patients for each group was power enough
to detect a difference there.
Dr Mark H. D. Danton (Glasgow, United Kingdom). Did you
have any patients whowere cyanotic in this group? One could con-
sider that if there were cyanotic patients with hypothermia, the col-
lateral flow may be increased as the systemic vasoconstriction
takes place with hypothermia. Therefore, you may have a differ-
ence, you may have better perfusion to the kidneys and the end or-
gans with normothermic bypass with cyanotic patients.
Dr Caputo. Yes, this is possible. Unfortunately, in this series,
there are very few cyanotic patients. The reason is that this was
clashing with another trial in which we were particularly studying
cyanotic patients and reoxygenation injuries. So unfortunately, I
cannot answer that question, but it is something we will look at
in the future, specifically targeting cyanotic patients.
Dr Emile A. Bacha (New York, NY).What was the temperature
of your cardioplegia?
DrCaputo. It was cold blood cardioplegia in this series, so 4C.
Dr Bacha. At 4C?
Dr Caputo. Yes, standard.
Dr Bacha. What kind of flows were you running?
Dr Caputo. These patients were at 2.5 L.
Dr Bacha. I assume the same flows in both groups.
Dr Caputo. Yes.diovascular Surgery c Volume 142, Number 5 1121
